Developing novel biological therapies targeting myeloid malignancies
The Wang Lab conducts acute myeloid leukemia (AML) preclinical research to find novel, synergistic treatments that target AML cells and leukemic stem cells in normal and hypoxic conditions.
Our research focuses on a variety of mechanisms, including DNA repair, DNA damage, apoptosis, autophagy, mitophagy, and cell cycle.
AML is a highly heterogeneous disease, with a vital need for novel treatments that are targeted and better tolerated.Read the research
We’re studying several promising new drugs, including combination therapy with crenolanib and frontline treatment with gilteritinib.See the science